OncoMatch/Clinical Trials/NCT06566079
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Is NCT06566079 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ISM6331 for malignant mesothelioma.
Treatment: ISM6331 — This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
Check if I qualifyExtracted eligibility criteria
Cancer type
Mesothelioma
Tumor Agnostic
Disease stage
Required: Stage IV
Metastatic disease required
unresectable advanced or metastatic malignant mesothelioma or other solid tumors
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immune checkpoint therapy
Participants with malignant mesothelioma must have prior exposure to at least immune checkpoint therapy
Must have received: platinum-based chemotherapy
Participants with malignant mesothelioma must have prior exposure to at least...platinum-based chemotherapy
Cannot have received: TEAD inhibitor
Participants who have previously received a TEAD inhibitor
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine · Chicago, Illinois
- University Hospitals Cleveland Medical Center · Cleveland, Ohio
- University of Pennsylvania - Abramson Cancer Center · Philadelphia, Pennsylvania
- SCRI Oncology Partners · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify